The Effects of Acute Nitrate and Caffeine Co-ingestion on Discipline-Specific Exercise Performance.
6 de agosto de 2026 actualizado por: Poznan University of Physical Education
The Acute Effects of Dietary Nitrate (Beetroot Juice), Caffeine, and Their Combination on Discipline-Specific Exercise Performance, Lactate Kinetics, and Physiological Responses in Trained Functional Fitness Athletes and Elite Junior Swimmers.
The purpose of this study is to investigate the acute, separate, and combined ergogenic effects of dietary nitrate (beetroot juice, BJ) and caffeine (CAF) supplementation on discipline-specific athletic performance.
The project employs a double-blind, randomized, placebo-controlled, four-arm crossover design.
It evaluates two highly distinct, heterogeneous populations of athletes: (A) adult high-intensity functional training (HIFT/CrossFit/Hyrox) competitors performing the standardized Hyrox Physical Fitness Test (P'F'T), and (B) elite junior competitive swimmers (National Team members) performing a progressive 8 × 100 m swimming test.
The study will assess physical performance, lactate kinetics, subjective exertion, biochemical indices, psychological metrics, and gastrointestinal tolerance.
Descripción general del estudio
Estado
Estado
Aún no reclutando
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
This project addresses a critical gap in sports nutrition literature regarding the potential synergistic, additive, or antagonistic interactions of caffeine (CAF) and dietary nitrate (beetroot juice, BJ) when co-administered. While CAF acts primarily as an adenosine receptor antagonist in the central nervous system to enhance motor unit recruitment and decrease perceived exertion, BJ acts as a physiological precursor to nitric oxide, improving peripheral muscle contractility, mitochondrial efficiency, and muscle perfusion.
To evaluate whether these effects are universal or discipline-specific, the trial employs a two-population cohort design:
- Cohort A (HIFT/Hyrox): Investigates adult functional fitness athletes (aged 18-45) characterized by concurrent strength and endurance adaptations. They will perform the ecological Hyrox P'F'T.
- Cohort B (Elite Junior Swimmers): Investigates elite junior national team swimmers (aged 16-19) during their centralized training camp. They will undergo the standardized progressive 8 × 100 m step-test.
Furthermore, this study will analyze whether individual hematological markers (iron status) and biochemical profiles correlate with the magnitude of the ergogenic response to establish prospective predictive biomarkers for customized sports nutrition.
Tipo de estudio
Tipo de estudio
Intervencionista
Inscripción (Estimado)
Inscripción
112
Fase
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Estudio Contacto
Estudio Contacto
- Nombre: Natalia Główka, PhD
- Número de teléfono: +48691756944
- Correo electrónico: glowka@awf.poznan.pl
Ubicaciones de estudio
-
-
Wielkopolska
-
Poznan, Wielkopolska, Polonia, 61-871
- Poznań University of Physical Education
-
Contacto:
- Natalia Główka
- Número de teléfono: 691756944
- Correo electrónico: glowka@awf.poznan.pl
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
Acepta Voluntarios Saludables
Sí
Descripción
Inclusion Criteria:
A) Cohort A (HIFT / CrossFit / Hyrox):
- Aged 18-45 years.
- Minimum of 2 years of systematic HIFT/CrossFit/Hyrox training experience.
- Performing >4 training sessions per week.
- Ability to perform the HYROX Physical Fitness Test (P'F'T) and has participated in at least one official HYROX event.
- Possession of a valid medical certificate proving eligibility for competitive sports.
B) Cohort B (Competitive Junior Swimmers):
- Aged 16-19 years.
- Active member of the Polish Junior National Swimming Team.
- Minimum of 5 years of competitive swimming experience.
- Current training volume of at least 8-10 pool training sessions per week.
- Written informed consent obtained from both the participant and their legal guardian (for minors under 18).
C)Common Criteria for Both Cohorts:
- No history of cardiovascular, respiratory, metabolic, or musculoskeletal disease contradicting high-intensity exercise or stimulant intake.
- No known food allergies or adverse reactions to beetroot products or caffeine.
- No current use of medications that alter nitrate/caffeine metabolism (e.g., proton pump inhibitors, antibiotics, phosphodiesterase inhibitors).
- History of uneventful habituation to caffeine use during training/competition.
- Willingness to abstain from dietary supplements, antibacterial mouthwashes, alcohol, and high-nitrate foods for 48 hours prior to each testing session.
- Good general health and physical well-being.
Exclusion Criteria (Applicable to both cohorts):
- Occurrence of acute musculoskeletal injury or trauma during the study period.
- Any medical or health contraindications (including severe menstrual disorders, planned pregnancy, or breastfeeding).
- Failure or refusal to strictly adhere to the dietary, supplementation, and exercise testing protocols.
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Ciencia básica
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Cuadruplicar
Número de brazos
4
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: CAF + BJ (Active Co-ingestion)
Participants ingest a concentrated beetroot juice shot (~6.4 mmol / 400 mg nitrates) 3 hours before exercise, and a capsule of caffeine (Cohort A: 6 mg/kg body mass; Cohort B: 3 mg/kg body mass) 60 minutes before exercise.
|
Anhydrous caffeine administered orally in a hard gelatine capsule.
To address the unique physiological profiles of the two cohorts, a highly specific, differentiated dosing protocol is implemented: Cohort A (adult functional fitness athletes) will receive a high-performance dose of 6 mg/kg body mass, while Cohort B (elite junior swimmers) will receive a safe, youth-adapted dose of 3 mg/kg body mass.
In all experimental trials, the capsule is ingested exactly 60 minutes prior to the onset of the discipline-specific exercise test to match peak plasma caffeine concentration.
Concentrated beetroot juice (BJ) administered as a single, acute organic shot of 70 mL (Beet It Sport, James White Drinks Ltd., Ipswich, UK).
Each active shot contains approximately 400 mg (equivalent to ~6.4 mmol) of inorganic nitrate.
In contrast to chronic loading designs, this study evaluates purely acute effects; the shot is ingested exactly 3 hours (180 minutes) prior to the physical performance test to align with peak systemic concentration of plasma nitrite.
|
|
Comparador activo: CAF + PLBJ (Caffeine + Placebo BJ)
Participants ingest a nitrate-depleted beetroot juice shot (~0.04 mmol nitrates) 3 hours before exercise, and a capsule of caffeine (Cohort A: 6 mg/kg body mass; Cohort B: 3 mg/kg body mass) 60 minutes before exercise.
|
Anhydrous caffeine administered orally in a hard gelatine capsule.
To address the unique physiological profiles of the two cohorts, a highly specific, differentiated dosing protocol is implemented: Cohort A (adult functional fitness athletes) will receive a high-performance dose of 6 mg/kg body mass, while Cohort B (elite junior swimmers) will receive a safe, youth-adapted dose of 3 mg/kg body mass.
In all experimental trials, the capsule is ingested exactly 60 minutes prior to the onset of the discipline-specific exercise test to match peak plasma caffeine concentration.
Nitrate-depleted beetroot juice (Beet It, James White Drinks Ltd., Ipswich, UK) administered as a 70 mL shot.
This placebo is identical in taste, smell, appearance, packaging, and viscosity to the active concentrated shot, but has been selectively filtered to contain negligible nitrate levels (<0.4 mmol / ~25 mg of nitrates).
It is ingested exactly 3 hours prior to the exercise test.
|
|
Comparador activo: PLCAF + BJ (Placebo CAF + Beetroot Juice)
Participants ingest a concentrated beetroot juice shot (~6.4 mmol / 400 mg nitrates) 3 hours before exercise, and a placebo capsule (maltodextrin) 60 minutes before exercise.
|
Concentrated beetroot juice (BJ) administered as a single, acute organic shot of 70 mL (Beet It Sport, James White Drinks Ltd., Ipswich, UK).
Each active shot contains approximately 400 mg (equivalent to ~6.4 mmol) of inorganic nitrate.
In contrast to chronic loading designs, this study evaluates purely acute effects; the shot is ingested exactly 3 hours (180 minutes) prior to the physical performance test to align with peak systemic concentration of plasma nitrite.
Placebo capsule containing inert maltodextrin powder.
The capsule is identical in size, shape, weight, color (opaque), and texture to the active caffeine capsule to ensure robust blinding.
It is administered at the exact same time point (60 minutes pre-exercise) according to the identical body-mass-adjusted dosing scheme (simulating either 3 mg/kg or 6 mg/kg).
|
|
Comparador de placebos: PLCAF + PLBJ (Double Placebo Control)
Participants ingest a nitrate-depleted beetroot juice shot (~0.04 mmol nitrates) 3 hours before exercise, and a placebo capsule (maltodextrin) 60 minutes before exercise.
|
Nitrate-depleted beetroot juice (Beet It, James White Drinks Ltd., Ipswich, UK) administered as a 70 mL shot.
This placebo is identical in taste, smell, appearance, packaging, and viscosity to the active concentrated shot, but has been selectively filtered to contain negligible nitrate levels (<0.4 mmol / ~25 mg of nitrates).
It is ingested exactly 3 hours prior to the exercise test.
Placebo capsule containing inert maltodextrin powder.
The capsule is identical in size, shape, weight, color (opaque), and texture to the active caffeine capsule to ensure robust blinding.
It is administered at the exact same time point (60 minutes pre-exercise) according to the identical body-mass-adjusted dosing scheme (simulating either 3 mg/kg or 6 mg/kg).
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Exercise Performance Time (minutes and seconds, Cohort A - Hyrox P'F'T)
Periodo de tiempo: At each experimental visit (Visits T1-T4), with visits conducted at 7-day intervals following the baseline/familiarization visit (T0).
|
Total time (in minutes and seconds) required to complete the standardized HYROX Physical Fitness Test (P'F'T) consisting of 6 specific functional exercises.
|
At each experimental visit (Visits T1-T4), with visits conducted at 7-day intervals following the baseline/familiarization visit (T0).
|
|
Swimming Performance (minutes and seconds, Cohort B - 8x100m Step-Test)
Periodo de tiempo: At each experimental visit (Visits T1-T4), with visits conducted at 7-day intervals following the baseline/familiarization visit (T0).
|
Swimming performance will be assessed using the completion time (seconds and milliseconds) for each 100-m repetition of the standardized 8 × 100-m step test, including the maximal-effort repetition performed during the fifth stage.
|
At each experimental visit (Visits T1-T4), with visits conducted at 7-day intervals following the baseline/familiarization visit (T0).
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Blood Lactate Kinetics (mmol/L)
Periodo de tiempo: Before supplementation (baseline), pre-exercise (3 hours after beetroot juice supplementation and 30 minutes after caffeine supplementation), and 3 and 7 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
Blood lactate concentration, including peak concentration, accumulation kinetics, and clearance rate, will be assessed from fingertip capillary blood collected before supplementation (baseline), pre-exercise (3 hours after beetroot juice supplementation and 30 minutes after caffeine supplementation), and post-exercise (3 and 7 minutes after exercise) at each experimental visit.
|
Before supplementation (baseline), pre-exercise (3 hours after beetroot juice supplementation and 30 minutes after caffeine supplementation), and 3 and 7 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
Heart Rate (HR, bpm)
Periodo de tiempo: Continuously monitored during exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
Real-time heart rate (beats per minute) will be continuously monitored throughout each exercise test using a telemetry-based heart rate monitoring system.
|
Continuously monitored during exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
Rating of Perceived Exertion (RPE, points)
Periodo de tiempo: Immediately after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
Subjective rating of perceived exertion will be assessed using the validated Borg Scale (6-20).
|
Immediately after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
Blood Pressure (mmHg)
Periodo de tiempo: Measured 2.5 hours after beetroot juice supplementation and 30 minutes after caffeine supplementation (pre-exercise) at each experimental visit (Visits T1-T4; 7-day intervals).
|
Systolic and diastolic blood pressure will be measured using an automated oscillometric blood pressure monitor.
|
Measured 2.5 hours after beetroot juice supplementation and 30 minutes after caffeine supplementation (pre-exercise) at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
Gastrointestinal Tolerance Profile (mVAS, points)
Periodo de tiempo: Measured 30 minutes after supplementation and immediately after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
Gastrointestinal symptoms will be assessed using the modified Visual Analog Scale (mVAS; 0-10, where 0 = no symptoms and 10 = extremely severe symptoms).
|
Measured 30 minutes after supplementation and immediately after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
White blood cells count and differential (count/L)
Periodo de tiempo: Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline) and 3 minutes after exercise at each experimental visit.
|
Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
White blood cells count and differential (%)
Periodo de tiempo: Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline) and 3 minutes after exercise at each experimental visit.
|
Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
Hematological indices (red blood cells, RBC) (count/L)
Periodo de tiempo: Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline) and 3 minutes after exercise at each experimental visit.
|
Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
Hematological indices (hemoglobin concentration, HGB) (mmol/L)
Periodo de tiempo: Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline) and 3 minutes after exercise at each experimental visit.
|
Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
Hematological indices (hematocrit, HCT) (L/L)
Periodo de tiempo: Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline) and 3 minutes after exercise at each experimental visit.
|
Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
Hematological indices (mean corpuscular volume, MCV; mean platelet volume, MPV) (fL)
Periodo de tiempo: Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline) and 3 minutes after exercise at each experimental visit.
|
Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
Hematological indices (mean corpuscular hemoglobin mass, MCH) (fmol)
Periodo de tiempo: Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline) and 3 minutes after exercise at each experimental visit.
|
Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
Hematological indices (mean corpuscular hemoglobin concentration, MCHC) (mmol/L)
Periodo de tiempo: Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline) and 3 minutes after exercise at each experimental visit.
|
Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
Hematological indices (platelet count, PLT) (count/L)
Periodo de tiempo: Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline) and 3 minutes after exercise at each experimental visit.
|
Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
Hematological indices (platelet hematocrit, PCT) (cL/L)
Periodo de tiempo: Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline) and 3 minutes after exercise at each experimental visit.
|
Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
Hematological indices (platelet distribution width, PDW; platelet large cell ratio, PLCR; red blood cells distribution width - coefficient of variation, RDW-C) (%)
Periodo de tiempo: Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline) and 3 minutes after exercise at each experimental visit.
|
Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
Hematological indices (red blood cells distribution width - standard deviation, RDW-S) (fL)
Periodo de tiempo: Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
Assessment of the hematological parameter will be performed from fingertip capillary blood collected before supplementation (baseline) and 3 minutes after exercise at each experimental visit.
|
Before supplementation (baseline) and 3 minutes after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
Nutritional status indices (concentration of urea) (mmol/L)
Periodo de tiempo: Before supplementation (baseline) at each experimental visit (Visits T1-T4; 7-day intervals).
|
Urea concentration will be assessed from fingertip capillary blood collected before supplementation (baseline).
|
Before supplementation (baseline) at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
Creatinine Concentration (μmol/L)
Periodo de tiempo: Before supplementation (baseline) at each experimental visit (Visits T1-T4; 7-day intervals).
|
Creatinine concentration will be assessed from fingertip capillary blood collected before supplementation (baseline).
|
Before supplementation (baseline) at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
Muscle Damage Markers (ALT, AST, CK, LDH) (U/L)
Periodo de tiempo: Before supplementation (baseline) at each experimental visit (Visits T1-T4; 7-day intervals).
|
Activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatine kinase (CK), and lactate dehydrogenase (LDH) will be assessed from fingertip capillary blood collected before supplementation (baseline).
|
Before supplementation (baseline) at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
Body composition (fat-free mass, fat mass) (kg)
Periodo de tiempo: Before supplementation (baseline) at each experimental visit (Visits T1-T4; 7-day intervals).
|
Body composition will be assessed before supplementation (baseline) using bioelectrical impedance analysis.
|
Before supplementation (baseline) at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
Body composition (fat-free mass, fat mass) (%)
Periodo de tiempo: Before supplementation (baseline) at each experimental visit (Visits T1-T4; 7-day intervals).
|
Body composition will be assessed before supplementation (baseline) using bioelectrical impedance analysis.
|
Before supplementation (baseline) at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
Body composition (total body water) (L)
Periodo de tiempo: Before supplementation (baseline) at each experimental visit (Visits T1-T4; 7-day intervals).
|
Body composition will be assessed before supplementation (baseline) using bioelectrical impedance analysis.
|
Before supplementation (baseline) at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
Body composition (total body water) (%)
Periodo de tiempo: Before supplementation (baseline) at each experimental visit (Visits T1-T4; 7-day intervals).
|
Body composition will be assessed before supplementation (baseline) using bioelectrical impedance analysis.
|
Before supplementation (baseline) at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
Iron Status (Iron, Ferritin, UIBC, TIBC) (μg/dL)
Periodo de tiempo: Before supplementation (baseline) at each experimental visit (Visits T1-T4; 7-day intervals).
|
Serum iron concentration, ferritin concentration, unsaturated iron-binding capacity (UIBC), and total iron-binding capacity (TIBC) will be assessed from fingertip capillary blood collected before supplementation (baseline).
|
Before supplementation (baseline) at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
Iron Status (Transferrin Concentration) (g/L)
Periodo de tiempo: Before supplementation (baseline) at each experimental visit (Visits T1-T4; 7-day intervals).
|
Serum transferrin concentration will be assessed from fingertip capillary blood collected before supplementation (baseline).
|
Before supplementation (baseline) at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
Sleep Quality (Visual Analog Scale, VAS; points)
Periodo de tiempo: Before supplementation (baseline), pre-exercise, and immediately after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
Subjective sleep quality will be assessed using a Visual Analog Scale (VAS).
|
Before supplementation (baseline), pre-exercise, and immediately after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
Mood (Brunel Mood Scale, BRUMS; points)
Periodo de tiempo: Before supplementation (baseline), pre-exercise, and immediately after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
Mood state will be assessed using the Brunel Mood Scale (BRUMS).
|
Before supplementation (baseline), pre-exercise, and immediately after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
Competitive State Anxiety (Revised Competitive State Anxiety Inventory-2, CSAI-2R; points)
Periodo de tiempo: Before supplementation (baseline), pre-exercise, and immediately after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
Competitive state anxiety will be assessed using the Revised Competitive State Anxiety Inventory-2 (CSAI-2R).
|
Before supplementation (baseline), pre-exercise, and immediately after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
Felt Arousal (Felt Arousal Scale, FAS; points)
Periodo de tiempo: Before supplementation (baseline), pre-exercise, and immediately after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
Perceived arousal will be assessed using the Felt Arousal Scale (FAS).
|
Before supplementation (baseline), pre-exercise, and immediately after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
|
Feeling Scale (FS; points)
Periodo de tiempo: Before supplementation (baseline), pre-exercise, and immediately after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
Affective valence will be assessed using the Feeling Scale (FS).
|
Before supplementation (baseline), pre-exercise, and immediately after exercise at each experimental visit (Visits T1-T4; 7-day intervals).
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Natalia Główka, PhD, Poznan University of Physical Education, Department of Sports Dietetics
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
1 de octubre de 2026
Finalización primaria (Estimado)
Finalización primaria
30 de junio de 2029
Finalización del estudio (Estimado)
Finalización del estudio
30 de junio de 2029
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
17 de julio de 2026
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
31 de julio de 2026
Publicado por primera vez (Actual)
Publicado por primera vez
5 de agosto de 2026
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
7 de agosto de 2026
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
6 de agosto de 2026
Última verificación
Última verificación
1 de julio de 2026
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- ZDS2026_NG_001
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
SÍ
Descripción del plan IPD
The study protocol will be published as an open-access article.
Upon completion of the study, de-identified individual participant data (IPD) and relevant analytic code will be deposited in an open-access repository such as Zenodo or OSF, following the FAIR principles.
Marco de tiempo para compartir IPD
The study protocol will be available upon its publication.
The IPD and analytic code will be available starting from the date of the primary study results publication and will remain accessible for at least 5 years.
Criterios de acceso compartido de IPD
The study protocol will be published as an open-access article.
Upon completion of the study, de-identified individual participant data (IPD) and relevant analytic code will be deposited in an open-access repository such as Zenodo or OSF, in accordance with FAIR principles.
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .